Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Elizabeth Hougen | F | 62 | 24 years | |
| Richard Geary | M | 66 | 29 years | |
| Sanjay Bhanot | M | - | 24 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jack Lief | M | 78 | 18 years | |
| Amit Munshi | M | 56 | 6 years | |
| Harry F. Hixson | M | 84 | - | |
| Craig M. Audet | M | 59 | 5 years | |
| Tina Nova | M | 70 | 18 years | |
| Dan Kisner | M | 77 | 8 years | |
| Derek T. Chalmers | M | 60 | 7 years | |
| Randall E. Woods | M | 72 | 13 years | |
| Steven Engle | M | 69 | 3 years | |
| Christine Anna White | M | 72 | 12 years | |
| Phillip Schneider | M | 67 | 11 years | |
| Carolyn M. Felzer | F | - | - | |
| Samuel Yonren | M | - |
Pfizer Central Research
| - |
| Daniel Ripley | M | 63 | 6 years | |
| Eric P. Mirabel | M | - |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 12 years |
| Ethel M. Koczon | F | - | 5 years | |
| Joanne Quan | M | 60 | 2 years | |
| David Walsey | M | - | 4 years | |
| Louis J. Scotti | M | 68 | 12 years | |
| Charles Olson | M | 66 | 7 years | |
| Ronald L. Shazer | M | 56 | 1 years | |
| Jeffrey Su | M | - |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Amy Broidrick | F | 66 | 2 years | |
| Zheng Wei | M | 61 | 4 years | |
| David Slack | M | 61 | 4 years | |
| Hui Fang Liu | M | 64 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 6 years |
| Alan Glicklich | M | - | 1 years | |
| Elizabeth Ann Fagan | M | 74 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Nikhil Agarwal | M | - | 3 years | |
| Gary J. G. Atkinson | M | 71 | 5 years | |
| Brian Pollok | M | - |
Pfizer Central Research
| 4 years |
| Gary Glandon | M | 65 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 2 years |
| John A. McNeil | M | 59 | - | |
| Edward Hu | M | 61 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 7 years |
| Louis Lavigne | M | 75 | - | |
| Nigel R. A. Beeley | M | 72 | 5 years | |
| F. Andrew Dorr | M | - | 7 years | |
| Michael Kelly | M | 67 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Patrick M. Murphy | M | 67 | - | |
| Robert Hoffman | M | 58 | 18 years | |
| John LaMattina | M | 74 |
Pfizer Central Research
| - |
| Jon T. Holmlund | M | 67 | 7 years | |
| Duke K. Bristow | M | 67 | 3 years | |
| Lisa R. Grillone | M | 74 | 10 years | |
| Edgardo Baracchini | M | 64 | 4 years | |
| Susan Knudson | F | 60 | - | |
| Ashraf Hanna | M | 56 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 4 years |
| Arthur Levin | M | 70 | - | |
| Klara Dickinson-Eason | F | 57 | 2 years | |
| John Overington | M | - |
Pfizer Central Research
| - |
| Sanjaya Singh | M | - |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 54 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William R. Shanahan
- Personal Network